ecancermedicalscience最新文献

{"title":"Leveraging virtual communities of practice for cancer control in Africa: experiences from the Africa Cancer Research and Control ECHO.","authors":"Johnblack K Kabukye, Alice B S Nono Djotsa, Adedayo Joseph, Charles Muya, Benda N Kithaka, Mishka K Cira, Leshia Hansen, Annet Nakaganda","doi":"10.3332/ecancer.2025.1878","DOIUrl":"10.3332/ecancer.2025.1878","url":null,"abstract":"<p><strong>Background: </strong>The growing burden of cancer in Africa requires innovative approaches for enhancing the cancer workforce on the continent. Virtual communities of practice (VCoPs) are one such approach that can be utilised for continuous professional development, networking and sharing of cancer knowledge and best practices among different stakeholders.</p><p><strong>Objectives: </strong>To describe the experiences of a cancer VCoP, the Africa Cancer Research and Control ECHO, and illustrate short- and long-term outcomes that are relevant to enhancing the cancer workforce in Africa.</p><p><strong>Methods: </strong>We collected quantitative and qualitative data about the 2022/2023 Africa Cancer ECHO through (i) statistics from the video conferencing platform (number of participants per session) and (ii) a cross-section survey at the end of the curriculum year in June 2023 (participants' feedback about the sessions, learning and use of the knowledge and network from the ECHO). We also compared these data with evaluations of the ECHO from previous years, and conducted interviews with core community members to understand long-term outcomes regarding professional networking and collaboration.</p><p><strong>Results: </strong>The African Cancer ECHO has been running since 2018. Members meet regularly online to discuss different aspects of cancer control through didactical and case presentations. In 2022/2023, twelve 90-minute monthly sessions were held with an average of 33 attendees per session and 200 unique individuals from 14 African countries overall, plus additional representation from outside of Africa.Over the 4 years (2019/2020 to 2022/2023), different cancer control stakeholders participated in the Africa Cancer ECHO, including advocates, patients, clinicians, researchers and cancer planners. For each year, about 30% of the participants were new to the ECHO. The respondents were positive about the ECHO sessions and in agreement with the ECHO's learning and networking outcomes 70%-90% of the time. The interviews revealed long-term, practical outcomes of the Africa Cancer ECHO, including securing research funding, initiation of a new community of practice to specifically address cancer survivorship in Africa and scientific research collaborations resulting in at least six peer-reviewed publications and several conference abstracts.</p><p><strong>Conclusion: </strong>VCoPs, such as the Africa Cancer ECHO, have the potential to contribute to human resource capacity-building for cancer control in Africa through accessible and convenient peer learning, professional networking and collaboration. However, the identification and use of more robust evaluation tools and methods may provide a more comprehensive assessment of all of their benefits, including short and long-term outcomes.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"19 ","pages":"1878"},"PeriodicalIF":1.2,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12146562/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144257558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment outcomes and the associated factors among breast cancer patients in Tanzania: a retrospective cohort study.","authors":"Nashivai E Kivuyo, Daniel W Kitua, Martin E Chikelea, Mungeni A Misidai, Ally H Mwanga, Obadia V Nyongole, Larry O Akoko","doi":"10.3332/ecancer.2025.1874","DOIUrl":"10.3332/ecancer.2025.1874","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer (BC) is the second most prevalent cancer among women in sub-Saharan Africa. Despite dedicated efforts to enhance BC care in the region through improving diagnostic and treatment services, little is known about the treatment outcomes of BC patients and the predictors of outcomes in our local settings have not been enumerated. This study aimed to investigate the treatment outcomes and the associated factors among BC patients in Tanzania.</p><p><strong>Materials and methods: </strong>This was a retrospective cohort study at Muhimbili National Hospital and Ocean Road Cancer Institute in 2022. It involved female patients 18 years and above who were confirmed to have BC by histology. A sample size of 240 was determined to be adequate to detect a survival difference between the stages. Using Research Electronic Data Capture, clinical characteristics were collected from patients' treatment records and survival status was ascertained both by case notes or phone calls to patients or next of kin. Data were transferred into Statistical Package for the Social Sciences version 27 for subsequent analysis where continuous variables were summarised as proportions. We used chi-square and Fisher's exact tests to determine the association between various patients' characteristics and treatment outcomes. Kaplan-Meyer analysis was used to determine survival and a p-value less than 0.05 is considered statistically significant.</p><p><strong>Results: </strong>In total, 298 BC patients were studied with a mean age of 53.2 ± 13.6 (27-89). Invasive ductal carcinoma, parity and late stage at presentation were predominant features in these patients. A triple negative subtype was identified in 35.2% of the women. Only 27.9% and 33.6% of the patients received neoadjuvant and adjuvant chemotherapy respectively, while 8.1% of the patients were palliated. The overall 5 years survival was 29.7%, while being significantly poor in patients with advanced stages of the disease. Luminal subtypes, parity, menopausal status and age had some influence on BC survival among our patients but not in a significant manner.</p><p><strong>Conclusion: </strong>Mastectomy is predominantly offered to BC patients in Tanzania with no standardisation of use of chemo/radiation both in neo/adjuvant settings. Some important prognostic factors were missing including a lack of standardised work up of patients. With the predominance of advanced stage at presentation, BC carries unacceptable high mortality in Tanzania. Efforts to detect BC early, understand patients' perception of their disease and standardisation of care are needed to successfully implement treatment guidelines.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"19 ","pages":"1874"},"PeriodicalIF":1.2,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12146571/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144257576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The first thousand days in a newly established radiation oncology clinic: an evaluation study.","authors":"Harun Demir, İbrahim Babalıoğlu, Aslı Şahbaz, Mehmet Koç","doi":"10.3332/ecancer.2025.1875","DOIUrl":"10.3332/ecancer.2025.1875","url":null,"abstract":"<p><strong>Aim: </strong>The study aimed to determine the distribution of cancer and treatment characteristics in a recently started radiation oncology (RO) clinic and to examine the differences according to age groups and gender.</p><p><strong>Method: </strong>The medical records of 2,434 patients who underwent treatment at Konya City Hospital's RO clinic between June 2021 and March 2024 were retrospectively examined. Descriptive analyses and the chi-square method were applied.</p><p><strong>Results: </strong>The median age was 63 years. Age groupings revealed that, in young adults, breast cancer and central nervous system malignancies were the most common (56.1, 14.6%), in adults, breast cancer and lung cancer (42.0, 24.0%), and in older adults, lung cancer and gastrointestinal system (GIS) cancers (33.6, 17.4%) (<i>p</i> = 0.00). The metastatic stage rate was higher in men at the time of initial diagnosis (<i>p</i> = 0.00). Lung cancer was more common in metastatic patients, whereas breast cancer was more common in non-metastatic patients (<i>p</i> = 0.00). Neoadjuvant RT was most often used in GIS malignancies (<i>p</i> = 0.00), adjuvant RT was most often used in breast cancer, and definitive, palliative RT was most often used in lung cancer. The first stage of the disease had not been associated with the distance to the treatment facility (<i>p</i> = 0.43).</p><p><strong>Conclusion: </strong>Our research has revealed significant differences in the distribution of cancer, stage and the role of radiotherapy according to both age groups and gender in the practice of RO. These findings can be utilised as a model for more efficient health strategising.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"19 ","pages":"1875"},"PeriodicalIF":1.2,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12146561/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144257564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A pilot study on the neurocognitive effect of sorafenib on patients with desmoid tumours: the SORA-COG study.","authors":"Kamboji Sharanya, Lulu Abdul Khader, Fathima Shahama Oliyath Vazhayil, Ghazal Tansir, Vaishnavi Vishwas, Simran Kaur, Sameer Rastogi, Ratna Sharma","doi":"10.3332/ecancer.2025.1871","DOIUrl":"10.3332/ecancer.2025.1871","url":null,"abstract":"<p><strong>Introduction: </strong>Sorafenib is a multikinase tyrosine kinase inhibitor whose prolonged use may lead to cognitive impairment due to inhibition of angiogenesis. However, data on its impact on neurocognitive function in desmoid tumours (DTs) is lacking.</p><p><strong>Methods: </strong>We conducted a cross-sectional study enrolling 50 participants including 30 with DT on sorafenib (Group 1), 10 treatment-naive patients with DT (Group 2) and 10 healthy controls (Group 3). Questionnaire-based assessment was done using appearance anxiety inventory, Depression anxiety and stress questionnaire-21 (DASS-21), Hindi mental status examination (HMSE) and computer-based Cambridge neuropsychological test automated battery (CANTAB) neuropsychological tests. Statistical analysis was performed using GraphPad Prism software version 10 and individual groups were compared using Kruskal-Wallis test with <i>p</i> value of <0.05 considered significant.</p><p><strong>Results: </strong>50 participants had a median age of 29.91 years (25%-75% CI: 27.05-32.77 years), female predominance (<i>n</i> = 26, 52%), median duration of sorafenib 18.1 months (range: 6-60) at a median dose of 241.17 mg (range: 200-400). There was a statistically significant difference in anxiety (<i>p</i> = 0.0127) between Groups 1 (patients on sorafenib) and 3 (healthy controls), while other objective cognitive and neuropsychological parameters were comparable. There was a significant positive correlation between sorafenib duration and anxiety (<i>p</i> = 0.026) by DASS21, and a negative correlation between HMSE and mean five choice reaction time (<i>p</i> = 0.04).</p><p><strong>Conclusion: </strong>This is the first study to examine the neurocognitive effects of sorafenib in patients with DT. We exhibit significantly higher anxiety in patients with DT on sorafenib as compared to healthy controls. There was a significant correlation noted between anxiety and treatment duration. We propose further longitudinal studies to assess the effect of sorafenib in DT.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"19 ","pages":"1871"},"PeriodicalIF":1.2,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12146563/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144257528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Psychological distress and coping strategies among caregivers of children with cancer: a cross-sectional study.","authors":"Poonam Joshi, Gopichandran L, Uma Shanker Agrawal, Parveen, Rakesh Garg, Surya Kant Tiwari","doi":"10.3332/ecancer.2025.1872","DOIUrl":"10.3332/ecancer.2025.1872","url":null,"abstract":"<p><strong>Background: </strong>Caregivers of children with cancer often experience significant psychological distress exacerbated by financial constraints and role modifications. This study aimed to assess the prevalence of anxiety and depression among caregivers of children receiving cancer treatment and to examine their coping mechanisms.</p><p><strong>Methods: </strong>This cross-sectional study included 124 caregivers of children receiving chemotherapy at a tertiary care facility in Northern India. Inclusion criteria included caregivers more than 18 years of age, engaged in child care for at least 3 months, accompanying them for chemotherapy and understanding Hindi or English. Anxiety and depression were assessed using the Hospital Anxiety and Depression Scale. The coping strategies were evaluated using a Brief Coping Orientation to the Problem-Experienced inventory.</p><p><strong>Results: </strong>The mean age of the caregivers was 34.50 ± 7.60 years, with the majority being male (62.1%). Over one-third of the caregivers (37.9%) reported abnormal anxiety levels, while 44.4% exhibited borderline depression. A significant moderate positive correlation was found between anxiety and depression (<i>r</i> = 0.676, <i>p</i> < 0.001). The most commonly used coping mechanisms are active coping and self-distraction. Multiple regression analysis revealed self-blame, acceptance and planning as significant coping strategies for anxiety, while self-blame, planning and religion were significant for depression.</p><p><strong>Conclusion: </strong>A substantial proportion of the caregivers experienced anxiety and depression. Emotion-focused and problem-focused coping strategies were the most frequently employed. These findings highlight the need for psychosocial support and interventions to foster healthier coping skills among caregivers of children with cancer.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"19 ","pages":"1872"},"PeriodicalIF":1.2,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12146578/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144257561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validation of the Subjective Happiness Scale, Oxford Happiness Questionnaire and Pemberton Happiness Index among women with breast cancer in a multi-ethnic Asian setting.","authors":"Nithiya Sinarajoo, Yek-Ching Kong, Ranjit Kaur, Ros Suzanna Bustamam, Nur Fadhlina Abdul Satar, Sharminii Jaya-Prakason, Harenthri Devy Alagir Rajah, Mahmoud Danaee, Cheng-Har Yip, Nirmala Bhoo-Pathy","doi":"10.3332/ecancer.2025.1873","DOIUrl":"10.3332/ecancer.2025.1873","url":null,"abstract":"<p><strong>Background: </strong>It is uncertain if the current tools that are used to measure happiness in the general population are valid in women with breast cancer.</p><p><strong>Objective: </strong>We determined the psychometric properties of the Subjective Happiness Scale (SHS), Oxford Happiness Questionnaire (OHQ) and Pemberton Happiness Index (PHI) among women with breast cancer in a multi-ethnic Asian setting.</p><p><strong>Methods: </strong>The internal consistency and construct validity of the SHS, OHQ and PHI were assessed. Criterion validity was determined by measuring the correlations of the study tools with the relevant domains of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire 30 and the Depression, Anxiety and Stress Scale.</p><p><strong>Results: </strong>Cronbach's alpha of the SHS, OHQ and PHI ranged from 0.75 to 0.92. In the exploratory factor analyses, a one-factor model was recommended for SHS and PHI. A two-factor model was recommended for OHQ. Confirmatory factor analysis indicated that the two-factor model for OHQ demonstrated acceptable convergent and divergent validity with composite reliability >0.70. Both OHQ and SHS revealed a moderately positive correlation with health-related quality of life, and a moderately negative correlation with psychological distress.</p><p><strong>Conclusion: </strong>This study demonstrated that SHS and OHQ are valid and reliable tools to measure happiness among women with breast cancer in multi-ethnic Asian settings. While the PHI seems promising, we were unable to confirm its criterion validity in the current study.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"19 ","pages":"1873"},"PeriodicalIF":1.2,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12146574/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144257578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Milan system for reporting salivary gland cytopathology and cyto-histological correlation with special emphasis on cystic lesions-4 years study in a tertiary care institute.","authors":"Prateek Das, Nibedita Sahoo, Pranita Mohanty, Pallak Batalia, Ankita Pal","doi":"10.3332/ecancer.2025.1870","DOIUrl":"10.3332/ecancer.2025.1870","url":null,"abstract":"<p><strong>Introduction: </strong>The Milan System for Reporting Salivary Gland Cytopathology (MSRSGC) was proposed by the American Society of Cytopathology and the International Academy of Cytology to bring uniformity in the reporting and treatment protocol. Cystic component is a common finding in non-neoplastic, benign and malignant lesions of the salivary gland. Fine needle aspiration is challenging in these cases due to pre-analytic error resulting in a high probability of false negativity.</p><p><strong>Aim: </strong>To classify salivary gland lesions according to MSRSGC with special emphasis on cystic lesions and histological correlation.</p><p><strong>Materials and methods: </strong>The study included 214 cases of salivary gland Fine needle aspiration cytology (FNACs) and classified according to MSRSGC with calculation of risk of malignancy (ROM) for each category.</p><p><strong>Results: </strong>The most common age group affected was in the fourth - fifth decade (27.57%) and the common site was parotid gland. The majority of the cases belonged to the Milan category IVA (40.65%) and the least number in categories III and V (4.2%). Histopathology follow up was available in 50% of cases with the maximum number of surgery in category VI (78.5%). The highest ROM was for category VI (90.9%) followed by category V (83.3%). Cystic lesions constituted 22.64%, of which histopathological follow up was available in 64.58% of cases with a high ROM for category III and V(100%).</p><p><strong>Conclusion: </strong>The ROM for cystic lesions is quite high for all categories as compared to the proposed MSRSGC. We suggest that repeat guided FNAC with a rapid on-site evaluation or ancillary diagnostic techniques can increase the diagnostic accuracy, especially for category I, III and cystic lesions.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"19 ","pages":"1870"},"PeriodicalIF":1.2,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12146568/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144257575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cross-sectional evaluation of a peer educator-led empowerment initiative for improving participation in cervical precancer screening among female sex workers in Ghana.","authors":"Kofi Effah, Ethel Tekpor, Comfort Mawusi Wormenor, Joseph Emmanuel Amuah, Vida Kwawukume, Louisa Ademki Matey, Seyram Kemawor, Stephen Danyo, Esu Aku Catherine Morkli, Nana Owusu Mensah Essel, Emmanuel Timmy Donkoh, Patrick Kafui Akakpo","doi":"10.3332/ecancer.2025.1869","DOIUrl":"10.3332/ecancer.2025.1869","url":null,"abstract":"<p><strong>Purpose: </strong>Despite having an increased risk of HPV infection, female commercial sex workers (FCSWs) have low uptake of cervical screening. Among FCSWs in the Volta Region of Ghana referred for screening following peer education, we examined the prevalence of high-risk human papillomavirus (hr-HPV) and cervical lesions and modelled factors associated with these screening outcomes.</p><p><strong>Patients and methods: </strong>As part of the mPharma Ten Thousand Women Initiative, implemented between September and October 2022, 340 FCSWs in Ho and Aflao were recruited by peer educators. Screening involved MA-6000 testing (with full genotyping using the AmpFire HPV platform) and enhanced visual assessment (EVA) mobile colposcopy.</p><p><strong>Results: </strong>The FCSWs screened had a mean age of 31.9 (SD, 9.3) years. The prevalence of cervical lesions on mobile colposcopy was 9.8% (95% confidence intervals (CI), 4.9-14.7), while the prevalence of hr-HPV infection among the FCSWs was estimated at 28.0% (95% CI, 20.6-35.3). The commonest individual genotype was HPV68 (9.1%; 95% CI, 4.9-15.0), while the least common genotypes were HPV33 and HPV39 (each 0.7%; 95% CI, 0.0-3.8). FCSWs screened in Aflao maintained threefold higher odds of hr-HPV infection (aOR, 3.33; 95% CI, 1.18-9.40) and having clinically significant EVA findings was associated with approximately fivefold higher odds of hr-HPV infection (aOR, 4.64; 95% CI, 1.09-19.83; <i>p</i>-value = 0.038). Condom use at the time of screening was independently associated with decreased odds of hr-HPV infection (aOR, 0.14; 95% CI, 0.04-0.49; <i>p</i>-value = 0.002). HIV infection (aOR, 9.95; 95% CI, 1.19-83.37) and engagement in oral-genital contact (aOR, 5.56; 95% CI, 1.35-22.94) were associated with higher odds of clinically significant EVA findings.</p><p><strong>Conclusion: </strong>Our study underscores the urgent need for comprehensive and targeted interventions to reduce the burden of hr-HPV and the potential for cervical precancer/cancer among FCSWs in Ghana. We further highlight the importance of promoting continuous condom use among FCSWs during interactions with patrons and considering HIV status in the development and implementation of cervical precancer screening programs for FCSWs.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"19 ","pages":"1869"},"PeriodicalIF":1.2,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12146576/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144257533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Proton pump inhibitors reduce survival outcomes in patients treated with capecitabine: meta-analysis.","authors":"Dina Mohyeldeen, Waleed Arafat","doi":"10.3332/ecancer.2025.1868","DOIUrl":"10.3332/ecancer.2025.1868","url":null,"abstract":"<p><p>Proton pump inhibitors (PPIs) are widely used over-the-counter drugs. The interaction between capecitabine and PPIs is still ambiguous within the literature, with some discrepancies still being present regarding the risks, or benefits, of their concomitant use. This meta-analysis aims to analyse data from the literature regarding both the risk of PPIs on survival in patients treated with capecitabine, as well as their benefits regarding the incidence of hand-foot syndrome (HFS). A total of 17 studies were included after searching PubMed, Medline and Cochrane until October 2022 for the effect of PPIs on the treatment efficacy and pharmacokinetics, and incidence of HFS. Revman Ver. 5.3 was used for all statistical analyses. Our data showed a significant HFS reduction at a relative risk of 0.77 (95% CI: 0.70-085; <i>p</i> < 0.00001) in the PPI-using groups compared to control. Meta-analysis of studies assessing survival, however, showed a reduction in almost all survival aspects, most notably within the recurrence-free survival, with a hazard ratio of 1.75; 95% CI: 1.21-2.53; <i>p</i> = 0.003. Individual data incriminating the use of PPIs with capecitabine is quite limited; however, our robust survival data on around 30,000 patients gave significantly worse survival outcomes, particularly in the (neo)adjuvant setting.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"19 ","pages":"1868"},"PeriodicalIF":1.2,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12146577/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144257560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical characteristics and first-line palliative treatment patterns in 3,414 patients with advanced lung cancer in India.","authors":"Mehak Trikha, Vanita Noronha, Minit Shah, Vijay Patil, Nandini Menon, Ajaykumar Singh, Pratik Chandrani, Omshree Shetty, Rajiv Kumar Kaushal, Trupti Pai, Amit Janu, Nilendu Purandare, Kumar Prabhash","doi":"10.3332/ecancer.2025.1867","DOIUrl":"10.3332/ecancer.2025.1867","url":null,"abstract":"<p><p>Lung cancer, particularly non-small-cell lung cancer (NSCLC), is a major global health issue. In India, the complexity of managing this disease is heightened by diverse demographics, varying healthcare access and evolving epidemiological trends influenced by factors such as smoking and advancements in diagnostics. This study explores cancer demographics and first-line palliative treatment options. We conducted a retrospective analysis of 3,414 advanced lung cancer patients planned for palliative systemic therapy at our centre between March 2000 and June 2017. The mean age of the cohort was 56.7 interquartile range (IQR: 21-88) years with a male predominance (71.9%). Histological subtypes included adenocarcinoma (82.9%), squamous cell carcinoma (13.6%) and others (3.5%). Intrathoracic metastases were seen in 40.7% and intrathoracic and extrathoracic in 37.7% of patients. The extrathoracic sites were skeletal (32.5%), liver (14.4%), brain (13.7%) and adrenal gland (9.0%). The baseline Eastern Cooperative Oncology Group Performance status was 0 (8.3%), 1 (58.7%), 2 (20.7%), 3 (11.7%) and 4 in 0.6% of the patients. Epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) positivity rates were lower in smokers. Most patients (92.4%) received the first-line systemic therapy, predominantly platinum-based doublets (67.1%). Tyrosine kinase inhibitors were given to 51.8% of EGFR+, 48% of ALK+ and 54.1% of mutation-negative cases. This study provides crucial insights into lung cancer demographics and treatment patterns at a single tertiary care centre in India, highlighting an increase in female lung cancer cases, steady smoking rates and improved access to genetic testing and targeted therapies.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"19 ","pages":"1867"},"PeriodicalIF":1.2,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12146565/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144257530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}